Skip to main content

International Psoriasis Council

Advancing Knowledge. Improving Care.

IPC 2023 Think Tank Meeting Report Published in JID Innovations

Key highlights from the 2023 International Psoriasis Council (IPC) Think Tank Meeting have been published in JID Innovations, summarizing presentations from the Gunnar Lomholt Symposium in the Faroe Islands. Covering a diverse range of topics related to psoriasis research and treatment strategies, the report underscores the evolving understanding of the genetic basis, comorbidities, pathogenesis, and treatment strategies of psoriasis.

Presentations from the IPC Think Tank meeting offered a comprehensive exploration of historical, current, and future perspectives on psoriasis management, providing valuable insights into its evolutionary trajectory. The future holds promise for a more nuanced understanding as genetic insights, immunological memory, and real-world evidence converge to shape individualized and effective management strategies. In conclusion, the landscape of psoriasis management has shifted from historical genetic explorations to a modern era of data analytics and targeted therapeutics. Navigating this transition involves embracing historical lessons, leveraging current technologies, and advancing toward personalized treatment approaches. As we move forward, the ongoing advancements in psoriasis research and treatment offer hope for alleviating the burden of this chronic condition and improving the quality of life for affected individuals, signifying a significant paradigm shift in psoriasis patient care.

Reference

Proceedings of the Gunnar Lomholt Symposium during the IPC 2023 Think Tank at Faroe Islands, Friday, September 8, 2023. Xing Lai FY, Bachelez H, Gudjonsson J, et al. JID Innovations (2024). doi: https://doi.org/10.1016/j.xjidi.2024.100267.

Comments are closed.

Categories

Recent Posts

When Cancer and Psoriasis Coexist: New IPC Guidance Puts Clarity Where It Is Needed Most

Reframing Obesity in Psoriatic Disease: From Pharmacokinetic Barrier to Therapeutic Target

Psoriasis and Metabolic Health: What IPC’s Latest Publication Means for Clinical Practice

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026